Arsanis (NASDAQ:ASNS) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $25.33.
A number of equities research analysts recently commented on ASNS shares. Zacks Investment Research raised shares of Arsanis from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research note on Thursday, March 15th. Cantor Fitzgerald set a $26.00 price objective on shares of Arsanis and gave the company a “buy” rating in a research note on Thursday, March 15th. Finally, ValuEngine raised shares of Arsanis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
A number of hedge funds and other institutional investors have recently modified their holdings of ASNS. Monashee Investment Management LLC acquired a new stake in Arsanis in the 4th quarter valued at about $191,000. Millennium Management LLC acquired a new stake in Arsanis in the 4th quarter valued at about $299,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Arsanis during the 4th quarter worth about $504,000. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Arsanis during the 4th quarter worth about $3,436,000. 69.45% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ ASNS traded down $0.80 during trading hours on Monday, reaching $20.25. The company’s stock had a trading volume of 10,519 shares, compared to its average volume of 60,612. The stock has a market cap of $300.90 and a price-to-earnings ratio of -1.25. Arsanis has a fifty-two week low of $10.40 and a fifty-two week high of $28.69. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.17.
Arsanis (NASDAQ:ASNS) last issued its quarterly earnings data on Friday, March 9th. The company reported ($1.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.82). research analysts expect that Arsanis will post -4.57 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/14/arsanis-asns-given-average-recommendation-of-buy-by-brokerages.html.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.